Form 4: Guardant Health Executive Chris Freeman Reports Stock Transactions

Chris Freeman, Chief Commercial Officer of Guardant Health, reports the vesting of restricted stock units and subsequent tax withholding.

Summary

• On April 1, 2024, Chris Freeman, Chief Commercial Officer of Guardant Health, engaged in transactions involving the company's stock.
• Freeman acquired 1,929 shares of common stock through the vesting of restricted stock units.
• Simultaneously, 531 shares were disposed of to cover tax withholding obligations at a price of $20.25 per share.
• Following these transactions, Freeman directly owns 15,971 shares of Guardant Health common stock and 19,284 restricted stock units.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company executives. It's a standard practice for publicly traded companies and their officers.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies in the United States, ensuring transparency in insider trading activities.
• Companies like Exact Sciences (EXAS) and Illumina (ILMN), which operate in similar fields, also have executives who regularly file Form 4s to report stock transactions.
• The details disclosed in this filing, such as the number of shares and the price, are consistent with the level of information expected in such reports.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• The filing provides transparency to shareholders regarding executive compensation and stock ownership.

Key Dates